The National Health Service (NHS) in England has initiated the rollout of a significantly faster immunotherapy treatment for tens of thousands of cancer patients. This new injectable form of pembrolizumab, marketed as Keytruda, can be administered in approximately 60 seconds, drastically reducing the time patients spend in treatment compared to the traditional intravenous method.
Pembrolizumab is a widely used immunotherapy drug designed to help the body’s immune system detect and fight cancer cells. Traditionally, this medication has been administered intravenously, a process that can take up to an hour for each session, not including preparation and observation time. The introduction of its subcutaneous formulation means that the drug can now be injected directly under the skin, requiring only about a minute for administration. This innovation is expected to cut treatment times by up to 90%, offering a substantial benefit to both patients and healthcare providers.
The rapid injection is approved for use across over a dozen different cancer types, including lung cancer, melanoma, head and neck cancer, and some forms of bladder cancer, for patients who are currently receiving or are set to receive pembrolizumab. The move is anticipated to benefit tens of thousands of individuals across England, providing a more convenient and less disruptive treatment experience. For many, reducing clinic visits to just a few minutes could significantly improve their quality of life, allowing more time for personal activities and reducing the burden of travel and waiting.
This advancement marks a positive step in streamlining cancer care within the NHS. Beyond the immediate benefits to patients, the reduced administration time could also help alleviate pressure on chemotherapy units and healthcare staff, potentially increasing capacity for other vital treatments. It highlights an ongoing trend towards more efficient and patient-centric methods of drug delivery in oncology, paving the way for future innovations in treatment protocols.